Table 3.
Disease Status at Baseline | Average public direct medical cost (US$±SD) | Multiplier (95% CI) | |||
---|---|---|---|---|---|
Age and Sex | Age, Sex, and Smoking | Age, Sex, Smoking, and Intermediate Risk Factorsa | Age, Sex, Smoking, Intermediate Risk Factors, Diagnosis of Diabetes, and Medicationsb | ||
No CVD or moderate/severe CKD | 1709±6989 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
Heart diseases | 4335±11,119 | 1.55 (1.49,1.61) | 1.55 (1.49,1.62) | 1.49 (1.43,1.54) | 1.53 (1.47,1.59) |
Stroke | 4146±12,464 | 1.66 (1.60,1.72) | 1.65 (1.60,1.71) | 1.61 (1.55,1.67) | 1.66 (1.60,1.72) |
Moderate CKD | 5048±12,903 | 1.89 (1.82,1.97) | 1.89 (1.81,1.96) | 1.83 (1.76,1.90) | 1.80 (1.73,1.87) |
Severe CKD | 9346±16,042 | 4.16 (3.59,4.82) | 4.14 (3.57,4.80) | 3.95 (3.41,4.58) | 3.87 (3.34,4.47) |
Heart diseases include coronary heart disease and heart failure. Moderate CKD, eGFR 30–59 ml/min per 1.73 m2; severe CKD, eGFR 15–29 ml/min per 1.73 m2. The P values for all multiplier were <0.001 by generalized linear model with γ family and log link function. CI, confidence interval; CVD, cardiovascular disease.
Intermediate risk factors include systolic and diastolic BP, LDL cholesterol, body mass index, total cholesterol/HDL ratio, triglycerides, and fasting glucose at baseline.
Diagnosis of diabetes and medications include number of antihypertensive drugs used, use of antidiabetic drugs, and lipid-lowering drugs at baseline.